Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
-
New schizophrenia pill shows promise in major trial
Disease control Recruiting nowThis study tests a new drug called Ulotaront (SEP-363856) to see if it can reduce symptoms like hallucinations and delusions in people with schizophrenia. About 522 adults experiencing an acute episode will receive either the drug or a placebo for 6 weeks. The main goal is to mea…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New TB drug could cut treatment time by two months
Disease control Recruiting nowThis study tests whether a new drug called quabodepistat can shorten treatment for drug-resistant tuberculosis (TB) from 6 months to 4 months. About 532 adults and teens with rifampicin-resistant or multidrug-resistant TB will be randomly assigned to receive either the new shorte…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could help control PKU – phase 3 trial now recruiting
Disease control Recruiting nowThis study tests an experimental oral drug, JNT-517, for adults with phenylketonuria (PKU), a genetic condition that causes harmful buildup of phenylalanine (Phe). About 120 adults will receive either JNT-517 or a placebo for 6 weeks, then all will receive JNT-517 for nearly a ye…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New PKU drug JNT-517 moves to Long-Term safety trial
Disease control Recruiting nowThis Phase 3 study is testing the long-term safety of an oral drug called JNT-517 in 240 children and adults with phenylketonuria (PKU). All participants will receive the drug twice daily, with doses based on age and weight. The goal is to see if JNT-517 is safe to use over time …
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Hope for kids with rare kidney disease: drug trial aims to slow damage
Disease control Recruiting nowThis trial tests the safety of tolvaptan, a drug that helps the body remove extra water, in 20 children aged 28 days to 18 years with autosomal recessive polycystic kidney disease (ARPKD). The goal is to see if the drug can slow kidney function decline and reduce the need for dia…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug VIS171 enters human trials for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:25 UTC
-
Brain scan study tests new Drug's target binding in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study involves 18 healthy men to see how well the experimental drug MSP-2020 attaches to serotonin receptors in the brain. Researchers will also measure how much drug stays in the blood and check for side effects. The goal is to understand the drug's activity in …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New drug interaction study launches for repinatrabit
Knowledge-focused Recruiting nowThis early-stage trial is testing how the experimental drug repinatrabit interacts with several common medications, including birth control pills, metformin, and methotrexate. The study involves 48 healthy volunteers and will measure drug levels in the blood to see if combining t…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC